Gene Therapy Protein Sparcl1 Triggers Hair Cell Regrowth in Deaf Mouse Models

Sensorineural hearing loss, driven largely by irreversible hair cell damage, affects hundreds of millions of people worldwide and currently lacks any regenerative treatment. Unlike birds and fish, adult mammals cannot spontaneously regenerate cochlear hair cells because their inner ear supporting cells progressively lose the developmental plasticity needed to trans-differentiate into hair cells. This study investigates whether overexpressing the secretory protein Sparcl1 can reverse that age-related loss of plasticity and promote meaningful hair cell regeneration.

The researchers packaged the Sparcl1 gene into AAV-ie, an inner-ear-tropic AAV serotype with high cochlear tropism, and delivered it via round-window membrane injection in neonatal and adult mice. They also tested direct administration of recombinant Sparcl1 protein. In parallel, in vitro inner-ear organoid models were used to dissect cellular mechanisms. RNA sequencing of Sparcl1-overexpressing supporting cells was performed to map downstream transcriptional changes.

Key results showed that AAV-Sparcl1 successfully expanded inner-ear organoids and promoted hair cell differentiation markers in both neonatal and adult cochlear tissues. RNA-seq analysis identified two major mechanistic arms: upregulation of follistatin (Fst), a known activin antagonist that promotes progenitor cell proliferation, and broad extracellular matrix (ECM) remodeling that loosens the structural constraints on supporting cell identity. Importantly, recombinant Sparcl1 protein alone—without gene delivery—was also sufficient to induce supporting cell-to-hair cell differentiation in vivo, suggesting the protein's extracellular secretory activity is the primary driver rather than intracellular gene expression changes.

These findings are significant for several reasons. First, they identify a secreted protein as a regulator of inner ear regeneration, opening a drug-like therapeutic window that does not strictly require permanent gene editing. Second, the dual mechanism—proliferation via Fst and ECM remodeling—suggests Sparcl1 acts as a master reprogramming facilitator rather than a simple transcription factor. Third, successful in vivo hair cell induction in adult mice, where regeneration is far more difficult than in neonates, strengthens clinical translatability.

Caveats include the predominant use of neonatal mouse models, where supporting cell plasticity is inherently higher than in adult or aged ears. Functional hearing recovery (auditory brainstem response or DPOAE measurements) is not extensively detailed in the available abstract and front matter, leaving open questions about whether newly generated hair cells achieve electrophysiological maturity. Long-term safety and immune response data for AAV-ie delivery also require further characterization before human trials.